Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027

As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million

Merck strikes $6.7 billion deal to acquire terns, bolstering cancer pipeline

TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances

Avid Organics launches first commercial-scale bio-based glycolic acid at in-cosmetics Global

India’s largest glycolic acid manufacturer will unveil AviGa Bio HP70 on April 14, 2026

Pfizer warns shareholders against Tutanota’s mini-tender offer

Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer

LANXESS marks 40 yrs of animal disease defense 'Virkon S'

A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone

Cbio launches first-in-human trial for groundbreaking cervical cancer therapy

Zenex Animal Health makes strategic European play with VievePharm acquisition

VievePharm is renowned for its phytogenic formulations across livestock, equine, and pet care markets

Eli Lilly’s orforglipron outshines oral semaglutide in landmark diabetes trial

The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints

Novartis completes $12 billion acquisition of Avidity Biosciences

The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity

Mankind Pharma overhauls global supply chain with AI

The initiative, delivered in collaboration with Accenture, integrates digitally enabled operating models powered by advanced analytics and AI across the company’s procurement, manufacturing, and distribution networks